Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Neurologia i Neurochirurgia Polska
MENU
Shortcuts Submit an article Guide for Authors Special collections Ahead Of Print Reviewers 2023

open access

Vol 53, No 5 (2019)
Research Paper
Submitted: 2019-05-01
Accepted: 2019-08-14
Published online: 2019-10-17
View PDF Download PDF file
Get Citation

Evaluating reflexive saccades and UDPRS as markers of Deep Brain Stimulation and Best Medical Treatment improvements in Parkinson’s disease patients: a prospective controlled study

Stanisław Szlufik1, Andrzej Przybyszewski2, Justyna Dutkiewicz1, Tomasz Mandat3, Piotr Habela2, Dariusz Koziorowski1
DOI: 10.5603/PJNNS.a2019.0045
·
Pubmed: 31621890
·
Neurol Neurochir Pol 2019;53(5):341-347.
Affiliations
  1. Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Poland
  2. Department of Informatics, Polish Japanese Academy of Information Technology, Warsaw, Poland
  3. Department of Neurosurgery, Maria Sklodowska Curie Memorial Oncology Center, Warsaw, Poland

open access

Vol 53, No 5 (2019)
Research papers
Submitted: 2019-05-01
Accepted: 2019-08-14
Published online: 2019-10-17

Abstract

Introduction. To date, there has been no clear evidence regarding the evaluation of saccades as a monitoring tool of motor impairment in Parkinson’s disease (PD) Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) patients. The aim of this study was to evaluate the long-term impact of STN-DBS and pharmacological treatment on reflexive saccades’ (RS) parameters and UPDRS alterations.

Material and methods. The DBS group consisted of 20 PD patients who underwent bilateral STN-DBS. The Postoperative (POP) group consisted of 14 post-DBS patients. The Best Medical Therapy (BMT) group consisted of 20 patients on pharmacotherapy only. RS parameters and the UPDRS scale were measured during three visits in four phases of treatment (i.e. BMT-ON/OFF, DBS-ON/OFF).

Results. The significant UPDRS III and UPDRS. Total improvements were observed in all three study groups (p < 0.05), but RS latency improvement was stated only in the DBS group in the DBS-ON phase (p < 0.05). A significant correlation between RS latency increase and UPDRS III score worsening was found in all study groups, with the most evident effect in the UPDRS III ON phase (p < 0.05).

Conclusion. RS parameters correlated with UPDRS III outcomes during the postoperative period in DBS-STN patients. Therefore, saccadic evaluation may be a good biomarker of the patient’s response to surgical and/or pharmacological treatment.

Abstract

Introduction. To date, there has been no clear evidence regarding the evaluation of saccades as a monitoring tool of motor impairment in Parkinson’s disease (PD) Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) patients. The aim of this study was to evaluate the long-term impact of STN-DBS and pharmacological treatment on reflexive saccades’ (RS) parameters and UPDRS alterations.

Material and methods. The DBS group consisted of 20 PD patients who underwent bilateral STN-DBS. The Postoperative (POP) group consisted of 14 post-DBS patients. The Best Medical Therapy (BMT) group consisted of 20 patients on pharmacotherapy only. RS parameters and the UPDRS scale were measured during three visits in four phases of treatment (i.e. BMT-ON/OFF, DBS-ON/OFF).

Results. The significant UPDRS III and UPDRS. Total improvements were observed in all three study groups (p < 0.05), but RS latency improvement was stated only in the DBS group in the DBS-ON phase (p < 0.05). A significant correlation between RS latency increase and UPDRS III score worsening was found in all study groups, with the most evident effect in the UPDRS III ON phase (p < 0.05).

Conclusion. RS parameters correlated with UPDRS III outcomes during the postoperative period in DBS-STN patients. Therefore, saccadic evaluation may be a good biomarker of the patient’s response to surgical and/or pharmacological treatment.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

Parkinson’s disease, BMT, DBS, reflexive saccades, marker

About this article
Title

Evaluating reflexive saccades and UDPRS as markers of Deep Brain Stimulation and Best Medical Treatment improvements in Parkinson’s disease patients: a prospective controlled study

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 53, No 5 (2019)

Article type

Research Paper

Pages

341-347

Published online

2019-10-17

Page views

1634

Article views/downloads

295

DOI

10.5603/PJNNS.a2019.0045

Pubmed

31621890

Bibliographic record

Neurol Neurochir Pol 2019;53(5):341-347.

Keywords

Parkinson’s disease
BMT
DBS
reflexive saccades
marker

Authors

Stanisław Szlufik
Andrzej Przybyszewski
Justyna Dutkiewicz
Tomasz Mandat
Piotr Habela
Dariusz Koziorowski

References (37)
  1. Krack P, Pollak P, Limousin P, et al. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease. Lancet. 1997; 350(9092): 1675.
    CrossRefPubMed
  2. Krack P, Batir A, Van Blercom N, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med. 1998; 339(16): 1105–1111.
    CrossRefPubMed
  3. Limousin P, Pollak P, Benazzouz A, et al. Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord. 1995; 10(5): 672–674.
    CrossRefPubMed
  4. Krack P, Limousin P, Benabid AL, et al. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. Lancet. 1997; 350(9092): 1676.
    CrossRefPubMed
  5. Fawcett AP, Dostrovsky JO, Lozano AM, et al. Eye movement-related responses of neurons in human subthalamic nucleus. Exp Brain Res. 2005; 162(3): 357–365.
    CrossRefPubMed
  6. Fawcett AP, Cunic D, Hamani C, et al. Saccade-related potentials recorded from human subthalamic nucleus. Clin Neurophysiol. 2007; 118(1): 155–163.
    CrossRefPubMed
  7. Sieger T, Bonnet C, Serranová T, et al. Basal ganglia neuronal activity during scanning eye movements in Parkinson's disease. PLoS One. 2013; 8(11): e78581.
    CrossRefPubMed
  8. Chan F, Armstrong IT, Pari G, et al. Deficits in saccadic eye-movement control in Parkinson's disease. Neuropsychologia. 2005; 43(5): 784–796.
    CrossRefPubMed
  9. Choi SM, Lee SH, Choi KH, et al. Directional asymmetries of saccadic hypometria in patients with early Parkinson's disease and unilateral symptoms. Eur Neurol. 2011; 66(3): 170–174.
    CrossRefPubMed
  10. Pinkhardt EH, Jürgens R, Lulé D, et al. Eye movement impairments in Parkinson's disease: possible role of extradopaminergic mechanisms. BMC Neurol. 2012; 12: 5.
    CrossRefPubMed
  11. Rivaud-Péchoux S, Vermersch AI, Gaymard B, et al. Improvement of memory guided saccades in parkinsonian patients by high frequency subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry. 2000; 68(3): 381–384.
    CrossRefPubMed
  12. Yugeta A, Terao Y, Fukuda H, et al. Effects of STN stimulation on the initiation and inhibition of saccade in Parkinson disease. Neurology. 2010; 74(9): 743–748.
    CrossRefPubMed
  13. Antoniades CA, Buttery P, FitzGerald JJ, et al. Deep brain stimulation: eye movements reveal anomalous effects of electrode placement and stimulation. PLoS One. 2012; 7(3): e32830.
    CrossRefPubMed
  14. Nilsson MH, Patel M, Rehncrona S, et al. Subthalamic deep brain stimulation improves smooth pursuit and saccade performance in patients with Parkinson's disease. J Neuroeng Rehabil. 2013; 10: 33.
    CrossRefPubMed
  15. Kumru H, Summerfield C, Valldeoriola F, et al. Effects of subthalamic nucleus stimulation on characteristics of EMG activity underlying reaction time in Parkinson's disease. Mov Disord. 2004; 19(1): 94–100.
    CrossRefPubMed
  16. Sauleau P, Pollak P, Krack P, et al. Subthalamic stimulation improves orienting gaze movements in Parkinson's disease. Clin Neurophysiol. 2008; 119(8): 1857–1863.
    CrossRefPubMed
  17. Temel Y, Visser-Vandewalle V, Carpenter RHS. Saccadometry: a novel clinical tool for quantification of the motor effects of subthalamic nucleus stimulation in Parkinson's disease. Exp Neurol. 2009; 216(2): 481–489.
    CrossRefPubMed
  18. Vermersch AI, Rivaud S, Vidailhet M, et al. Sequences of memory-guided saccades in Parkinson's disease. Ann Neurol. 1994; 35(4): 487–490.
    CrossRefPubMed
  19. Rascol O, Clanet M, Montastruc JL, et al. Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. Brain. 1989; 112 ( Pt 5): 1193–1214.
    CrossRefPubMed
  20. Michell AW, Xu Z, Fritz D, et al. Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. Exp Brain Res. 2006; 174(1): 7–18.
    CrossRefPubMed
  21. Hood AJ, Amador SC, Cain AE, et al. Levodopa slows prosaccades and improves antisaccades: an eye movement study in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007; 78(6): 565–570.
    CrossRefPubMed
  22. Yugeta A, Terao Y, Fukuda H, et al. Effects of levodopa on saccade performance in Parkinson’s disease. Mov Disord. 2008; 23(Suppl. 1): S296.
  23. Dec-Ćwiek M, Tutaj M, Gracies JM, et al. Opposite effects of l-dopa and DBS-STN on saccadic eye movements in advanced Parkinson's disease. Neurol Neurochir Pol. 2017; 51(5): 354–360.
    CrossRefPubMed
  24. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 1990; 13(7): 266–271.
    CrossRefPubMed
  25. Terao Y, Fukuda H, Ugawa Y, et al. New perspectives on the pathophysiology of Parkinson's disease as assessed by saccade performance: a clinical review. Clin Neurophysiol. 2013; 124(8): 1491–1506.
    CrossRefPubMed
  26. Deuschl G, Schade-Brittinger C, Krack P, et al. German Parkinson Study Group, Neurostimulation Section. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. 2006; 355(9): 896–908.
    CrossRefPubMed
  27. Weaver FM, Follett K, Stern M, et al. CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA. 2009; 301(1): 63–73.
    CrossRefPubMed
  28. Williams A, Gill S, Varma T, et al. PD SURG Collaborative Group. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol. 2010; 9(6): 581–591.
    CrossRefPubMed
  29. Schuepbach WMM, Rau J, Knudsen K, et al. EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013; 368(7): 610–622.
    CrossRefPubMed
  30. Movement Disorder Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord. 2003; 18(7): 738–750.
    CrossRefPubMed
  31. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988; 51(6): 745–752.
    CrossRefPubMed
  32. Defer GL, Widner H, Marié RM, et al. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord. 1999; 14(4): 572–584.
    PubMed
  33. Douglas Bates, Martin Maechler, Ben Bolker, Steve Walker . Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software. 2015; 67(1): 1–48.
  34. Lenth R. Least-Squares Means: TheRPackagelsmeans. Journal of Statistical Software. 2016; 69(1).
    CrossRef
  35. Hirshler YK, Polat U, Biegon A. Intracranial electrode implantation produces regional neuroinflammation and memory deficits in rats. Exp Neurol. 2010; 222(1): 42–50.
    CrossRefPubMed
  36. Orlowski D, Michalis A, Glud AN, et al. Brain Tissue Reaction to Deep Brain Stimulation-A Longitudinal Study of DBS in the Goettingen Minipig. Neuromodulation. 2017; 20(5): 417–423.
    CrossRefPubMed
  37. Colangelo AM, Alberghina L, Papa M. Astrogliosis as a therapeutic target for neurodegenerative diseases. Neurosci Lett. 2014; 565: 59–64.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl